ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2139 • ACR Convergence 2022

    Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

    Iain B McInnes1, Philipp Sewerin2, Mohamed Sharaf3, Michela Efficace4, May Shawi5, Michelle Perate6, Miriam Zimmermann7 and Laura Coates8, 1Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Janssen Cilag SpA, Imperia, Italy, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6Janssen Scientific Affairs, LLC, Horsham, PA, 7Janssen Scientific Affairs, LLC, Zug, Switzerland, 8Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody targeting the IL-23 p19 subunit. In the Phase 3b COSMOS trial (NCT03796858), GUS significantly improved disease signs/symptoms…
  • Abstract Number: 1966 • ACR Convergence 2022

    Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Eva van Geel1, Bafrin Abdulmajid1, Annelies Blanken2 and Michael Nurmohamed3, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Amsterdam University Medical Center, Kortenhoef, Netherlands

    Background/Purpose: Controlling inflammation with tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. Arterial wall thickness (carotid…
  • Abstract Number: 2145 • ACR Convergence 2022

    Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials

    Lars Erik1, Kim Papp2, Douglas White3, Cecilia Asnal4, Wenjing Lu5, Ahmed Soliman5, Byron Padilla6, Michael Chen5 and Andrew Ostor7, 1Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, 2K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, 3Rheumatology Department, Waikato Hospital, and Waikato Clinical School, University of Auckland, Hamilton, New Zealand, 4Hospital Alemán, Buenos Aires, Argentina, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Inc., Waukegan, IL, 7Cabrini Hospital, Monash University & Emeritus Research, Melbourne, Australia

    Background/Purpose: PsA is a chronic, systemic inflammatory disease with a variety of clinical manifestations including arthritis, enthesitis, and dactylitis and is associated with skin and…
  • Abstract Number: 2144 • ACR Convergence 2022

    JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis

    Maria Gabriella Raimondo1, Charles Gwellem Anchang1, Hannah Labinsky2, Mina Saad Aziz Saad1, Simon Rauber1, Mario Vogg1, Eleni Kampylafka1, Johannes Knitza1, Alina Soare1, Georg Schett3 and Andreas Ramming1, 1Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Janus Kinase (JAK)/Signal Transducers and Activator of Transcription (STAT) is not only involved in IL23- signaling, but rather implemented into a broad range of…
  • Abstract Number: 2132 • ACR Convergence 2022

    Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis

    Roy Fleischmann1, Diamant Thaci2, Melinda Gooderham3, Bruce Strober4, Neil J. Korman5, Subhashis Banerjee6, Tom Lehman6, Miroslawa Nowak6, Antoine Sreih7, Akimichi Morita8 and Philip J Mease9, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany, 3SKiN Centre for Dermatology, Queen’s University, Probity Medical Research, Peterborough, Canada, 4Yale University, New Haven, CT; Central Connecticut Dermatology Research, Cromwell, CT, 5Case Western Reserve University and University Hospitals, Cleveland, OH, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Myers Squibb, Philadelphia, PA, 8Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 9Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action distinct from Janus kinase (JAK)…
  • Abstract Number: 2089 • ACR Convergence 2022

    The Implication of Skin Involvement on Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients

    Alicia Van1, Vibeke Strand2, Jiandong Su1, Nicole Anderson1, Cheryl F Rosen3, Sherief Marzouk4, Lee S Simon5 and Zahi Touma1, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2Stanford University School of Medicine, Stanford, CA, 3University of Toronto, Toronto, ON, Canada, 4University Health Network, University of Toronto, Toronto, ON, Canada, 5SDG LLC, West Newton, MA

    Background/Purpose: Skin involvement in Systemic Lupus Erythematosus (SLE) occurs in 50-85% of patients making it one of the most commonly affected organs in SLE. Previous…
  • Abstract Number: 2025 • ACR Convergence 2022

    Natural History of Sjögren’s Disease from the National Institutes of Health Cohort

    Brandon Law1, Margaret Beach2, Eileen Pelayo2, Ilias Alevizos2, Zohreh Khavandgar2, Blake Warner2 and Alan Baer1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2National Institutes of Health, Bethesda, MD

    Background/Purpose: The objectives of this study were to assess the natural history of Sjögren's disease (SjD) over an interval reaching up to 32 years among…
  • Abstract Number: 2033 • ACR Convergence 2022

    Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology

    Maxwell Parker, Zihao Zheng, Quinn Parker, Addie Vande Loo, Michael Newton, Miriam Shelef and Sara McCoy, University of Wisconsin, Madison, WI

    Background/Purpose: SjD disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients…
  • Abstract Number: 2092 • ACR Convergence 2022

    Greater Social Vulnerability Associates with Greater Glucocorticoid Use in Patients with SLE

    Avira Som1, Lily McMorrow1, Ling Chen1, Deepali Sen1, Alia El-Qunni1, Elizabeth Baker2 and Alfred Kim1, 1Washington University School of Medicine, St. Louis, MO, 2Saint Louis University College for Public Health and Social Justice, St. Louis, MO

    Background/Purpose: Patients with SLE experience substantial health disparities. Studying the effect of spatial context on health outcomes has become a focus in health disparities research.…
  • Abstract Number: 1965 • ACR Convergence 2022

    Autoantibodies Against a Specific 25-mer Peptide from P. Gingivalis Are Present in Sera of Patients with Rheumatoid Arthritis and Early Arthritis

    Hsin-Yi Peng1, Ting-Yin Xue1, Fei-Hung Hsieh1, Yi-Ko Chen1, Mei-Chin Yin2, Che-Yi Chao2, Shu-Yao Tsai2, Chung-Ping Lin3, Po-Hao Huang3, Chien-Chung Huang3, Jiunn-Horng Chen3, Chung-Ming Huang3, Der-Yuan Chen4, Joung-Liang Lan5 and Gregory Tsay3, 1China Medical University, Taichung, Taiwan, 2Asia University, Taichung, Taiwan, 3China Medical University Hospital, Taichung, Taiwan, 4China Medical University Hospital Rheumatology and Immunology Center, Taichung, Taiwan, 5China Medoical University Hospital, Taichung, Taiwan

    Background/Purpose: The presence of rheumatoid factor (RF) or anti-cyclic citrullinated protein/peptide antibodies (ACPA) are included in the 2010 the ACR/EULAR classification criteria of rheumatoid arthritis…
  • Abstract Number: 2143 • ACR Convergence 2022

    Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment

    Louis Bessette1, Georg Pongratz2, Luca Navarini3, Rodrigo Garcia Salinas4, Tianming Gao5, Marie-Claude Laliberté6, Ralph Lippe7 and Philip J Mease8, 1Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 2Asklepios Clinic Bad Abbach, University of Regensburg, Regensburg, Germany, 3Rheumatology, Immunology, and Clinical Medicine, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy, 4Hospital Italiano de La Plata, La Plata, Argentina, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Québec, QC, Canada, 7AbbVie, Inc, Wiesbaden, Germany, 8Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Managing pain, a predominant symptom of psoriatic arthritis (PsA), is a priority for patients and healthcare providers. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor,…
  • Abstract Number: 2100 • ACR Convergence 2022

    Employment Trajectory of Canadian Young Adults with Systemic Lupus Erythematosus

    Lily Lim1, Menelaos Konstanidis2, Zahi Touma3, Diane Lacaille4, Umut Oguzoglu1, Christine Peschken1, Nicole Anderson3, Ramandeep Kaur1 and Eleanor Pullenayegum2, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Toronto, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 4Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Young adulthood (18-30 years) is a time of many changes. Young adults finish school, enter the labour force, and maybe start their own families.…
  • Abstract Number: 2036 • ACR Convergence 2022

    Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon

    Andres Martinez1, Julieta Morbiducci1, Constanza Arguissain1, Maria Tamborenea1, Marisel Bejarano2, Lucia Castorino1 and Anastasia Secco1, 1Rivadavia Hospital, Buenos Aires, Argentina, 2Rivadavia´s Hospital, Buenos Aires, Argentina

    Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease, and Raynaud's Phenomenon (RP) is an extraglandular manifestation that can evolve into a systemic sclerosis-overlap syndrome.…
  • Abstract Number: 1907 • ACR Convergence 2022

    Strength Training Associates with Less Knee Osteoarthritis: Data from the Osteoarthritis Initiative

    Grace Lo1, Michael Richard2, Timothy McAlindon3, Andrea Kriska4, Bonny Rockette-Wagner4, Charles Eaton5, Marc Hochberg6, Rebecca Jackson7, Kent Kwoh8, Michael Nevitt9 and Jeffrey Driban10, 1Baylor College of Medicine, Houston, TX, 2Tufts Medical Center, Boston, MA, 3Tufts Medical Center, Arlington, MA, 4University of Pittsburgh, Pittsburgh, PA, 5Brown University, Pawtucket, RI, 6University of Maryland School of Medicine, Baltimore, MD, 7The Ohio State University, Columbus, OH, 8University of Arizona, Tucson, AZ, 9University of California San Francisco, Orinda, CA, 10Tufts Medical Center, Westborough, MA

    Background/Purpose: Engagement in strength training has become increasingly popular and is an activity that can involve weight-bearing, heavy lifting, and frequent knee bending; and thus…
  • Abstract Number: 1636 • ACR Convergence 2022

    Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort

    Murray Urowitz1, Mary E. Georgiou2, Jiandong Su3, Anne MacKinnon3, Yulia Green4, Kerry Gairy2, Roger A Levy5 and Patricia C. Juliao6, 1University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 2GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, 3University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Division of Rheumatology, Toronto, ON, Canada, 4GlaxoSmithKline, Clinical Development, Brentford, United Kingdom, 5GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 6GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA

    Background/Purpose: Approximately 40% of adult patients with SLE develop LN, which can lead to end-stage kidney disease (ESKD).1 Renal response is used in clinical trials…
  • « Previous Page
  • 1
  • …
  • 411
  • 412
  • 413
  • 414
  • 415
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology